Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multicenter parallel-group randomized study

P. Barone, L. Scarzella, R. Marconi, A. Antonini, L. Morgante, F. Bracco, M. Zappia, B. Musch, M. T. Pellecchia, M. Amboni, A. Schiatti, Sadia Carapelli, G. Pezzoli, S. Tesei, A. Epifanio, E. Gasparoli, G. Arabia, M. G. Papini, A. Battaglia

Research output: Contribution to journalArticle

Abstract

In addition to treating the motor symptoms of Parkinson's disease, the dopamine agonist pramipexole has shown an antidepressant effect. The trials, however, included patients with motor complications, raising the question of whether the antidepressant benefit represented only a treatment-related motor improvement. To address this issue, we have conducted a 14-week randomized trial comparing pramipexole with an established antidepressant in patients without motor complications. At seven Italian centers, 67 Parkinsonian outpatients with major depression but no history of motor fluctuations and/or dyskinesia received open-label pramipexole (at 1.5 to 4.5 mg/day) or sertraline (at 50 mg/day). In both groups, the Hamilton Depression Rating Scale (HAM-D) score decreased throughout 12 weeks of treatment, but in the pramipexole group the proportion of patients who recovered, as defined by a final HAM-D score ≤ 8,was significantly higher, at 60.6% versus 27.3% (p = 0.006). Patients' self-ratings improved in both groups. All adverse events were mild or moderate, but five patients (14.7%) withdrew from the sertraline group. Despite the absence of motor complications, the pramipexole recipients showed improvement on the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscore. We conclude that dopamine agonists may be an alternative to antidepressants in Parkinson's disease.

Original languageEnglish
Pages (from-to)601-607
Number of pages7
JournalJournal of Neurology
Volume253
Issue number5
DOIs
Publication statusPublished - May 2006

Keywords

  • Depression
  • Parkinson's disease
  • Pramipexole
  • Sertraline

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multicenter parallel-group randomized study'. Together they form a unique fingerprint.

  • Cite this

    Barone, P., Scarzella, L., Marconi, R., Antonini, A., Morgante, L., Bracco, F., Zappia, M., Musch, B., Pellecchia, M. T., Amboni, M., Schiatti, A., Carapelli, S., Pezzoli, G., Tesei, S., Epifanio, A., Gasparoli, E., Arabia, G., Papini, M. G., & Battaglia, A. (2006). Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multicenter parallel-group randomized study. Journal of Neurology, 253(5), 601-607. https://doi.org/10.1007/s00415-006-0067-5